Comparison of methods for detection of plasmid-mediated and chromosomally encoded colistin resistance in Enterobacteriaceae by Jayol, Aurélie et al.
ϭ
Comparison of methods for detection of plasmid-mediated and ϭ
chromosomally-encoded colistin resistance in Enterobacteriaceae Ϯ
Aurélie Jayol,1,2,3,4 Patrice Nordmann,3,4,5 Philippe Lehours,1 Laurent Poirel,3,4 and ϯ
Véronique Dubois1,2*ϰ
1Laboratory of Bacteriology, Bordeaux University Hospital, 2CNRS UMR5234, University of ϱ
Bordeaux, France, 3Emerging Antibiotic Resistance Unit, Medical and Molecular ϲ
Microbiology, Department of Medicine, University of Fribourg, Switzerland, 4INSERM ϳ
European Unit (LEA, IAME), Paris, France, and 5University of Lausanne and University ϴ
hospital Center, Lausanne, Switzerland ϵ
ϭϬ
Keywords. MCR-1, colistin, polymyxin B, resistance, susceptibility testing, Phoenix ϭϭ
automated system, Rapid Polymyxin NP test ϭϮ
ϭϯ
*Corresponding author. Véronique Dubois, MFP Laboratory CNRS UMR-5234. 146 rue Léoϭϰ
Saignat, Batiment 3A, 33076 BORDEAUX Cedex, France. E-mail: veronique.dubois@u-ϭϱ
bordeaux.fr ϭϲ
ϭϳ
ϭϴ
ϭϵ
ϮϬ
Ϯϭ
ϮϮ
Ϯϯ
Ϯϰ
Published in "Clinical Microbiology and Infection doi: 10.1016/j.cmi.2017.06.002,  2017"
which should be cited to refer to this work.
Ϯ

ABSTRACT Ϯϱ
Ϯϲ
Objectives: Because of the emergence of plasmid-mediated (mcr-1 and mcr-2 genes) and Ϯϳ
chromosomally-encoded colistin resistance, reliable methods for detecting colistin Ϯϴ
resistance/susceptibility in routine laboratories are required. We evaluated the respective Ϯϵ
performances of the BD Phoenix automated system, the newly-developed Rapid Polymyxin ϯϬ
NP test and the broth microdilution (BMD) reference method to detect colistin resistance in ϯϭ
Enterobacteriaceae, and particularly those producing MCR-1 and MCR-2. ϯϮ
Methods: Colistin susceptibility of 123 enterobacterial clinical isolates (40 colistin-ϯϯ
susceptible and 83 colistin-resistant isolates) was tested with the Phoenix automated system, ϯϰ
the Rapid Polymyxin NP test and the BMD method. Molecular mechanisms responsible for ϯϱ
plasmid-mediated and chromosomally-encoded colistin resistance mechanisms were ϯϲ
investigated by PCR and sequencing. ϯϳ
Results: Considering BMD as a reference method, the Phoenix system failed to detect ten ϯϴ
colistin-resistant isolates (one Escherichia coli, one Klebsiella pneumoniae, seven ϯϵ
Enterobacter spp., and one Salmonella enterica). The Rapid Polymyxin NP test failed to ϰϬ
detect the same single E. coli isolate. Those two latter methods detected the sixteen E. coli, K. ϰϭ
pneumoniae and S. enterica isolates producing the plasmid-encoded MCR-1 and MCR-2. ϰϮ
Conclusion: The Phoenix system and the Rapid Polymyxin NP test are reliable techniques for ϰϯ
detecting plasmid-mediated MCR-1 and MCR-2-related colistin resistance. However, a high ϰϰ
rate of false susceptibility was observed with the Phoenix system, indicating that ϰϱ
susceptibility results obtained with that system should be confirmed by BMD method. By ϰϲ
contrast, the Rapid Polymyxin NP test showed a good agreement with the BMD method and ϰϳ
ϯ

results were obtained rapidly (within two hours). The BMD method should be performed if ϰϴ
MIC values are needed.  ϰϵ
ϱϬ
ϰ

INTRODUCTION ϱϭ
The increasing use of colistin in human medicine, and the recent discovery of plasmid-ϱϮ
mediated polymyxin resistance [1–4], highlight the need for reliable methods for polymyxin ϱϯ
susceptibility testing. ϱϰ
The Clinical Laboratory Standard Institute (CLSI) and the European Committee on ϱϱ
Antimicrobial Susceptibility Testing (EUCAST) recently gathered in a joint subcommittee, ϱϲ
chose the broth microdilution (BMD) method as the reference method (www.eucast.org). It ϱϳ
must be performed with sulfate salts of polymyxins (colistimethate used in human medicine ϱϴ
shall not be used), with cation-adjusted Mueller-Hinton broth, without additive (in particular ϱϵ
without polysorbate 80) and without treated polystyrene trays. Other methods such as, agar ϲϬ
dilution, disk diffusion and gradient diffusion (E-test) have been ruled out. However, this gold ϲϭ
standard BMD method is difficult to performed in routine laboratories since it requires ϲϮ
qualified staff, is time-consuming, and requires manual preparation of antibiotic solutions [5].  ϲϯ
Automated dilution methods such as those performed by the BD Phoenix system could ϲϰ
be an alternative for the screening of colistin resistance for laboratories that cannot perform ϲϱ
manual BMD. However, the performance of this automate for colistin susceptibility testing, ϲϲ
especially its accuracy for the detection of isolates exhibiting a plasmid-mediated colistin ϲϳ
resistance, have never been evaluated. Recently, a rapid colorimetric test, the Rapid ϲϴ
Polymyxin NP test, has been developed for detecting polymyxin resistance in ϲϵ
Enterobacteriaceae within 2 hours [6]. ϳϬ
 The objective of this study was to evaluate the performance of the BD Phoenix ϳϭ
automated system to detect plasmid-mediated and chromosomally-encoded colistin resistance, ϳϮ
using a collection of clinical enterobacterial isolates. We also aimed to compare their ϳϯ
performances to those of the Rapid Polymyxin NP test and the BMD reference method.ϳϰ
ϱ

MATERIAL AND METHODS ϳϱ
Bacterial strains. This study was carried out using 123 non-duplicated clinical ϳϲ
isolates of various enterobacterial species. The collection included 40 colistin-susceptible and ϳϳ
83 colistin-resistant isolates. Out of the 83 colistin-resistant isolates, sixteen belonged to a ϳϴ
genus known to be naturally-resistant to colistin (Morganella, Proteus, Providencia, Serratia,ϳϵ
Hafnia), and 67 isolates belonged to the Escherichia, Klebsiella, Enterobacter, or SalmonellaϴϬ
genus with acquired resistance mechanisms to colistin. Identification of the isolates at the ϴϭ
species level was performed using the Microflex bench-top MALDI-TOF mass spectrometer ϴϮ
(Brücker, Champs-sur-Marne, France). Isolates were grown on Luria Bertani (LB) ϴϯ
(GibcoBRL, Cergy Pontoise, France) or Mueller Hinton (MH) (bioMérieux, Marcy-l’Etoile, ϴϰ
France) agar plates at 35±2°C for 18 h. The colistin-susceptible E. coli ATCC 25922 strain ϴϱ
was included in all experiments as quality control.ϴϲ
Susceptibility testing ϴϳ
Reference antimicrobial susceptibility testing ϴϴ
The BMD method was performed according to the EUCAST/CLSI joined guidelines ϴϵ
(www.eucast.org). Briefly, BMD panels were prepared extemporaneously in 96-wells sterile ϵϬ
polystyrene microplates (Sarstedt, Nümbrecht, Germany). Dilutions of colistin (Sigma Aldrich, ϵϭ
St Louis, USA) ranging from 0.125 to 128 mg/l were made in cation-adjusted MH broth (Bio-ϵϮ
Rad, Marnes-la-Coquette, France), without addition of polysorbate 80 (Tween 80), and with a ϵϯ
final concentration of 5x105 CFU/ml of bacteria in each well. This procedure was performed ϵϰ
in triplicate in separate experiments and the Minimum Inhibitory Concentrations (MICs) were ϵϱ
read after 16 to 20 h of incubation at 35±2°C in ambient air. Results were interpreted ϵϲ
according to the EUCAST breakpoints [7], i.e. isolates with MICs of colistin  2 mg/l were ϵϳ
categorized as susceptible although those with MICs > 2 mg/l were resistant.  ϵϴ
ϲ

BD Phoenix automated system ϵϵ
Colistin susceptibility testing was assessed using the Phoenix automated system (BD Phoenix ϭϬϬ
100, BD Diagnostic systems, Le Pont de Claix, France), which performs automated BMD ϭϬϭ
method. The panel selected to perform this evaluation was the Gram-negative panel NMIC-ϭϬϮ
93, using the BMD method for colistin concentrations ranging from 0.5 to 4 mg/l in order to ϭϬϯ
cover the EUCAST breakpoints [7]. The bacterial suspension and the panel inoculation were ϭϬϰ
performed according to the manufacturer’s guidelines. Panels were incubated up to 16 h at ϭϬϱ
35±2°C under ambient air, and results were interpreted with the BD EpiCenter software. ϭϬϲ
Rapid Polymyxin NP test ϭϬϳ
The Rapid Polymyxin NP test is based on the detection of the glucose metabolism related to ϭϬϴ
bacterial growth in presence of a fixed concentration of colistin (3.75 mg/l) in cation-adjusted ϭϬϵ
MH broth medium [6]. Formation of acid metabolites consecutive to the glucose metabolism ϭϭϬ
is evidenced by a color change (orange to yellow) of the pH indicator (red phenol). The test is ϭϭϭ
positive (colistin resistance) if a strain grows in presence of colistin, whereas it is negative ϭϭϮ
(colistin susceptibility) if a strain does not grow in presence of colistin. Results of the Rapid ϭϭϯ
Polymyxin NP test were read at 2 h of incubation at 35±2°C in ambient air. ϭϭϰ
Molecular characterization of the colistin resistance. Molecular mechanisms ϭϭϱ
responsible for plasmid-mediated (mcr-1 and mcr-2 genes) and chromosomally-encoded ϭϭϲ
(pmrA, pmrB, phoP, phoQ, mgrB, and crrB alterations) colistin resistance were determined as ϭϭϳ
described previously [1,2,8–12]. ϭϭϴ
Results analysis. The results obtained with the BD Phoenix system and the Rapid ϭϭϵ
Polymyxin NP test were compared to those obtained with the reference BMD method. ϭϮϬ
Discrepancies were determined for each method in order to assess their performance to detect ϭϮϭ
colistin resistance. For strains for which discrepant susceptibility results were obtained, the ϭϮϮ
ϳ

isolates were retested with the three methods. Unsolved discrepancies were then maintained in ϭϮϯ
the database for performance evaluation. Errors were ranked as follows: a very major error ϭϮϰ
(VME) was defined when isolates were categorized as susceptible using the Phoenix system ϭϮϱ
or the Rapid Polymyxin NP test but resistant by the BMD method (false-susceptible result), ϭϮϲ
while a major error (ME) was defined when isolates were found resistant using the Phoenix ϭϮϳ
system or the Rapid Polymyxin NP test, but were found susceptible by using the BMD ϭϮϴ
method (false-resistant result). The number of resistant isolates, and the number of susceptible ϭϮϵ
isolates were used as denominators for VME and ME calculations, respectively. Acceptance ϭϯϬ
criteria that provide requirements, and specifications to evaluate performances of ϭϯϭ
antimicrobial susceptibility test devices were those defined by the ISO standards (VME and ϭϯϮ
ME must be 3%) [13].  ϭϯϯ
RESULTS ϭϯϰ
The features of the 123 enterobacterial isolates included in this study to evaluate the ϭϯϱ
performance of the BD Phoenix system and the Polymyxin NP test for determining colistin ϭϯϲ
susceptibility are presented in the Table.  ϭϯϳ
Fourty isolates defined as colistin-susceptible according to the results of the BMD ϭϯϴ
method (MICs of colistin ranging from 0.12 to 2 μg/ml) were found susceptible by the BD ϭϯϵ
Phoenix system (Table). While a single susceptible K. pneumoniae isolate with an MIC of ϭϰϬ
colistin at 2 mg/l was found resistant using the Rapid Polymyxin NP test. The MIC value of ϭϰϭ
colistin for this same isolate as determined by the BD Phoenix system was underestimated ϭϰϮ
(MIC  0.5 mg/l) but the isolate was well categorized as susceptible. ϭϰϯ
Out of the 83 colistin-resistant enterobacterial isolates (MICs of colistin ranging from ϭϰϰ
4 to higher than 128 mg/l), the Phoenix system failed to detect colistin resistance for seven ϭϰϱ
Enterobacter spp. isolates, a single K. pneumoniae, a single S. enterica, and a single E. coliϭϰϲ
ϴ

isolate, whereas the Rapid Polymyxin NP test only failed for detecting a single colistin-ϭϰϳ
resistant E. coli isolate. (Table). Identical results were obtained when those strains were ϭϰϴ
repeatedly tested with the Phoenix system and the Rapid Polymyxin NP test indicating a good ϭϰϵ
reproducibility of the methods.  ϭϱϬ
 Noteworthy, thirteen non clonally-related colistin-resistant E. coli, one K. pneumoniae,ϭϱϭ
and one S. enterica isolate possessing the plasmid-mediated mcr-1 gene were tested (MICs of ϭϱϮ
colistin ranging from 4 to 64 mg/l using the BMD method) and all were identified as resistant ϭϱϯ
with the BD Phoenix system and the Rapid Polymyxin NP test. Similarly, the E. coli isolate ϭϱϰ
possessing the plasmid-mediated mcr-2 gene (MIC = 4 mg/l) was detected by the two ϭϱϱ
methods.  ϭϱϲ
DISCUSSION ϭϱϳ
 Out of the 40 colistin-susceptible enterobacterial isolates, no ME (i.e. false resistance) ϭϱϴ
was found with the Phoenix system, and only a single susceptible K. pneumoniae isolate with ϭϱϵ
an MIC of colistin at 2 mg/l (therefore just below the EUCAST breakpoint value > 2 mg/l) ϭϲϬ
was falsely identified as colistin resistant with the Rapid Polymyxin NP test revealing a ME ϭϲϭ
rate of 2.5%.test ϭϲϮ
Out of the 83 colistin-resistant enterobacterial isolates, the BD Phoenix system and the ϭϲϯ
Rapid Polymyxin NP test showed excellent performances to detect the 13 isolates with ϭϲϰ
plasmid-mediated colistin resistance regardless of the level of resistance. However, ten VME ϭϲϱ
(i.e. false susceptibility) were found with the Phoenix system whereas a single VME was ϭϲϲ
found with the Rapid Polymyxin NP test (Table). A high VME rate of 12% was thus found ϭϲϳ
with the BD Phoenix system, whereas a low VME rate of 1.2% was found with the Rapid ϭϲϴ
Polymyxin NP test. The single colistin-resistant E. coli isolate that was not detected with the ϭϲϵ
BD Phoenix system and the Rapid Polymyxin NP test, presented a low level of resistance ϭϳϬ
ϵ

(MIC of colistin at 8 mg/l). Its mechanism of colistin resistance remains unknown (neither ϭϳϭ
chromosomally-encoded mutations in genes known to be involved in lipopolysaccharide ϭϳϮ
modifications, i.e. mgrB, pmrAB and phoPQ genes, nor plasmid-mediated mcr-1 and mcr-2ϭϳϯ
genes were detected).     ϭϳϰ
The S. enterica isolate identified as susceptible (MIC = 2 mg/l) with the BD Phoenix system ϭϳϱ
presented a low level of colistin resistance (MIC = 4 mg/l) and its mechanism of resistance ϭϳϲ
remains unknown (neither chromosomal mutations, nor plasmid-mediated resistance). ϭϳϳ
The K. pneumoniae resistant isolate and the seven Enterobacter spp. resistant isolates not ϭϳϴ
detected with the BD Phoenix system exhibited MIC values of colistin ranging from 16 to ϭϳϵ
higher than 128 mg/l and were identified as colistin resistant with the Rapid Polymyxin NP ϭϴϬ
test. During the determination of MICs by the BMD method, skipped wells (i.e. wells that ϭϴϭ
exhibit no growth although growth does occur at higher concentrations) were observed for ϭϴϮ
88% of those isolates (the K. pneumoniae isolate and six Enterobacter spp. isolates). This ϭϴϯ
observation suggests that the failure of the BD Phoenix system to detect colistin resistance in ϭϴϰ
those isolates could be related to a heteroresistance phenotype (defined by the presence of two ϭϴϱ
subpopulations exhibiting different susceptibilities to colistin) [14]. The skipped wells ϭϴϲ
observed during the MIC determination of those isolates by the BMD method are mainly for ϭϴϳ
dilutions comprised between 0.125 and 4 mg/l. The Phoenix panel used in this study ϭϴϴ
contained dilutions of colistin ranging from 0.5 to 4 mg/l. It is therefore likely that the failure ϭϴϵ
of detection of heteroresistance for those isolates was linked to the absence of testing at higher ϭϵϬ
colistin concentrations. The low sensitivity to detect colistin heteroresistance has already been ϭϵϭ
described for another automated system, i.e. the bioMérieux Vitek system [15]. ϭϵϮ
The limitation of our study could be the absence of testing of non-fermenting Gram negative ϭϵϯ
rods in our collection. ϭϵϰ
ϭϬ

CONCLUSION ϭϵϱ
This study shows that the BD Phoenix system and the Rapid Polymyxin NP test are ϭϵϲ
reliable tools for detection of plasmid-mediated colistin resistance (mcr-1 and mcr-2 genes), ϭϵϳ
which is currently a major concern. However, the BD Phoenix system is not reliable for ϭϵϴ
detection of colistin heteroresistance in enterobacterial isolates. Thus, we recommend the ϭϵϵ
determination of MICs by the BMD method when susceptible results are obtained and if ϮϬϬ
clinical use is required. By contrast, the Rapid Polymyxin NP test showed a good agreement ϮϬϭ
with the BMD method and results were obtained rapidly (within two hours), but BMD ϮϬϮ
method should be performed if determination of MIC values is necessary.  ϮϬϯ
ϮϬϰ
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Table. MICs of colistin (mg/l) using the BMD method and the BD Phoenix system and results of the Rapid Polymyxin NP test.  
Isolate Species Phenotype Mechanism of resistance to 
colistina
BMD Phoenix  Rapid Polymyxin NP test 
(number of isolates) MIC colistin MIC colistin Discrepanciesb Result Discrepanciesb,c
Isolates susceptible to colistin 
ATCC25922 E. coli S NA 0.25 0.5 No - No 
2 to 15 E. coli (n= 14) S NA 0.12 to 0.5 0.5 No - No 
16 to 26 K. pneumoniae 
(n=11)
S NA 0.12 to 2 0.5 No - Yes, ME (n=1)
27 to 29 K. oxytoca (n=3) S NA 0.12 to 0.25 0.5 No - No 
30 to 32 E. cloacae (n=3) S NA 0.12 to 0.25 0.5 No - No 
33 E. asburiae S NA 0.12 0.5 No - No 
34 E. aerogenes S NA 0.12 0.5 No - No 
35 to 37 C. freundii (n=3) S NA 0.25 0.5 No - No 
38 to 40 C. koseri (n=3) S NA 0.12 to 0.25 0.5 No - No 
Isolates resistant to colistin 
41 M. morganii R Intrinsic >128 >4 No + No 
42-43 P. mirabilis (n=2) R Intrinsic >128 >4 No + No 
44 P. vulgaris R Intrinsic >128 >4 No + No 
45 P. stuartii R Intrinsic >128 >4 No + No 
46 to 48 S. marcescens (n=3) R Intrinsic >128 >4 No + No 
49 to 52 H. alvei (n=4) R Intrinsic 8 or 16 4 or >4 No + No 
53 to 56 H. paralvei (n=4) R Intrinsic 8 4 or >4 No + No 
57 to 68 E. coli (n= 11) R Plasmid-mediated mcr-1 gene 4 or 8 4 or >4 No + No 
69 E. coli R Plasmid-mediated mcr-1 gene 64 >4 No + No 
70 E. coli R Plasmid-mediated mcr-2 gene 4 4 No + No 
71 K. oxytoca R ISKpn26 into mgrB promotor 64 >4 No + No 
72 E. coli R Unknown 8 0.5 Yes, VME - Yes, VME 
73 E. coli R Unknown 8 >4 No + No 
74 E. coli R Unknown 4 4 No + No 
75 E. coli R Unknown 16 >4 No + No 
76 K. pneumoniae R PmrA G53C 64 >4 No + No 
77-78 K. pneumoniae (n=2) R PmrA G53S 16 or 32 >4 No + No 
79-80 K. pneumoniae (n=2) R PmrB T157P 16 or 32 >4 No + No 
81 K. pneumoniae R PhoP D191Y 128 0.5 Yes, VME + No 
82 K. pneumoniae R PhoQ R16C 128 >4 No + No 
83 K. pneumoniae R MgrB N42Y et K43I  64 >4 No + No 
84 K. pneumoniae R MgrB I45T 64 >4 No + No 
85 to 87 K. pneumoniae (n=3) R MgrB truncated 64 or 128 >4 No + No 
88 K. pneumoniae R Deletion of 11 nucleotides into 
mgrB gene 
>128 >4 No + No 
89 K. pneumoniae R blaCTX-M-15/ISEcp1 into mgrB 64 >4 No + No 
90 K. pneumoniae R IS5 into mgrB gene 64 >4 No + No 
91 K. pneumoniae R IS102 into mgrB gene >128 >4 No + No 
92 K. pneumoniae R ISKpn14 into mgrB gene 32 >4 No + No 
93 K. pneumoniae R ISKpn13 into mgrB gene 128 >4 No + No 
94 K. pneumoniae R ISKpn26 into mgrB gene 64 >4 No + No 
95 K. pneumoniae R IS903 into mgrB gene 128 >4 No + No 
96 K. pneumoniae R IS903b into mgrB gene 64 >4 No + No 
97 K. pneumoniae R IS5 into mgrB gene 128 >4 No + No 
98 K. pneumoniae R IS10R into mgrB promotor 128 >4 No + No 
99 K. pneumoniae R ISKpn14 into mgrB promotor 32 >4 No + No 
100 K. pneumoniae R CrrB N141Y  >128 >4 No + No 
101 K. pneumoniae R CrrB P151L >128 >4 No + No 
102 K. pneumoniae R CrrB G183V >128 >4 No + No 
103 K. pneumoniae R Plasmid mediated mcr-1 gene 16 4 No + No 
104 K. pneumoniae R Unknown 16 >4 No + No 
105 K. pneumoniae R Unknown 64 >4 No + No 
106 K. pneumoniae R Unknown 32 >4 No + No 
107 K. pneumoniae R Unknown >128 >4 No + No 
108 K. pneumoniae R Unknown 64 >4 No + No 
109 K. pneumoniae R Unknown 64 >4 No + No 
110 K. pneumoniae R Unknown 32 >4 No + No 
111 E. cloacae R Unknown 32 >4 No + No 
112 E. cloacae R Unknown >128 >4 No + No 
113 E. cloacae R Unknown 32 >4 No + No 
114 E. cloacae R Unknown >128 1 Yes, VME + No 
115 E. cloacae R Unknown 64 0.5 Yes, VME + No 
116 E. cloacae R Unknown >128 0.5 Yes, VME + No 
117 E. cloacae R Unknown 16 0.5 Yes, VME + No 
118 E. cloacae R Unknown >128 0.5 Yes, VME + No 
119 E. cloacae R Unknown >128 0.5 Yes, VME + No 
120 E. asburiae R Unknown >128 0.5 Yes, VME + No 
121 S. enterica R Plasmid mediated mcr-1 gene 16 >4 No + No 
122 S. enterica R Unknown 4 2 Yes, VME + No 
123 S. enterica R Unknown 4 >4 No + No 
S, susceptible; R, resistant; NA, not applicable. 
aUnknown : no mutation in genes known to be involved in colistin resistance (pmrA, pmrB, phoP, phoQ, mgrB and crrB genes) 
bVME, very major error (false-susceptibility compared to the results obtained by broth microdilution reference method) 
cME, major error (false-resistance compared to the results obtained by broth microdilution reference method) 
